We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The dyslipidaemia market.
- Authors
Hudson, Victoria
- Abstract
The article presents forecasts for the dyslipidaemia market for 2014-2021. It predicts that rosuvastatin will face generic competition in the U.S. from May 2016 and the statin class will continue to dominate the dyslipidaemia market due to the availability of cheap and efficacious statins. Also discussed are the treatment options for dyslipidaemia, a major risk factor for cardiovascular diseases (CVDs), including statin, fibrates and ion-exchange resins.
- Subjects
UNITED States; DYSLIPIDEMIA; PHARMACEUTICAL industry forecasting; ROSUVASTATIN; CARDIOVASCULAR diseases risk factors; FIBRATES; ION exchange resins; ECONOMIC competition; THERAPEUTICS
- Publication
Nature Reviews Drug Discovery, 2014, Vol 13, Issue 11, p807
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd4475